MX2021015447A - Métodos de tratamiento del cáncer dirigidos a tumores fríos. - Google Patents

Métodos de tratamiento del cáncer dirigidos a tumores fríos.

Info

Publication number
MX2021015447A
MX2021015447A MX2021015447A MX2021015447A MX2021015447A MX 2021015447 A MX2021015447 A MX 2021015447A MX 2021015447 A MX2021015447 A MX 2021015447A MX 2021015447 A MX2021015447 A MX 2021015447A MX 2021015447 A MX2021015447 A MX 2021015447A
Authority
MX
Mexico
Prior art keywords
cancer treatment
treatment methods
methods directed
fluoro
patients
Prior art date
Application number
MX2021015447A
Other languages
English (en)
Spanish (es)
Inventor
Brian Fox
Ellen Filvaroff
Ida Aronchik
Tracy Chow
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2021015447A publication Critical patent/MX2021015447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021015447A 2019-06-13 2020-06-12 Métodos de tratamiento del cáncer dirigidos a tumores fríos. MX2021015447A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861094P 2019-06-13 2019-06-13
PCT/US2020/037521 WO2020252331A1 (en) 2019-06-13 2020-06-12 Methods of treating cancer by targeting cold tumors

Publications (1)

Publication Number Publication Date
MX2021015447A true MX2021015447A (es) 2022-04-06

Family

ID=73781074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015447A MX2021015447A (es) 2019-06-13 2020-06-12 Métodos de tratamiento del cáncer dirigidos a tumores fríos.

Country Status (10)

Country Link
US (1) US12357633B2 (https=)
EP (1) EP3983016A4 (https=)
JP (1) JP2022536412A (https=)
KR (1) KR20220024426A (https=)
CN (1) CN115135324A (https=)
AU (1) AU2020290508A1 (https=)
CA (1) CA3143030A1 (https=)
IL (1) IL288939A (https=)
MX (1) MX2021015447A (https=)
WO (1) WO2020252331A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114398A1 (en) * 2020-03-06 2023-01-11 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
CN113421613B (zh) * 2021-06-08 2024-06-18 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法
AU2024337882A1 (en) * 2023-09-07 2026-02-19 Sutter Bay Hospitals Co-targeting ncoa3 and pd-1 for cancer therapy
CN117538544A (zh) * 2023-11-22 2024-02-09 湛江中心人民医院 检测基因Ccdc181表达量的试剂在制备精子异常诊断产品中的应用
KR20250143182A (ko) * 2024-03-21 2025-10-01 차의과학대학교 산학협력단 시스플라틴에 대한 반응성의 예후를 나타내는 비소세포폐암 환자의 분류를 위한 분석방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160116474A1 (en) * 2013-06-20 2016-04-28 The Broad Institute, Inc. Compositions and methods for detecting and treating glioblastoma
KR102400920B1 (ko) 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
LT3371152T (lt) * 2015-11-05 2021-04-12 Celgene Quanticel Research, Inc. Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui
US11998540B2 (en) * 2015-12-11 2024-06-04 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
ES2972741T3 (es) 2016-08-10 2024-06-14 Celgene Quanticel Res Inc Tratamiento del carcinoma de células de Merkel
MA51507A (fr) * 2016-12-09 2020-11-11 Constellation Pharmaceuticals Inc Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Also Published As

Publication number Publication date
AU2020290508A1 (en) 2022-01-27
IL288939A (en) 2022-02-01
KR20220024426A (ko) 2022-03-03
US12357633B2 (en) 2025-07-15
CA3143030A1 (en) 2020-12-17
WO2020252331A1 (en) 2020-12-17
EP3983016A1 (en) 2022-04-20
US20220273654A1 (en) 2022-09-01
JP2022536412A (ja) 2022-08-16
CN115135324A (zh) 2022-09-30
EP3983016A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
ZA202409114B (en) MODULATORS OF THR-ß AND METHODS OF USE THEREOF
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202006137B (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
JOP20200315B1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
PH12021550443A1 (en) Pyridazinones and methods of use thereof
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
JOP20250057A1 (ar) مركبات لعلاج السرطان
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
WO2021242844A8 (en) Grk2 inhibitors and uses thereof